We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amarin is a member of the Medical sector. This group includes 918 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 26.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AMRN has moved about 2.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 1.6%. This means that Amarin is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Royalty Pharma (RPRX - Free Report) . The stock is up 56.8% year-to-date.
For Royalty Pharma, the consensus EPS estimate for the current year has increased 5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual companies and currently sits at #162 in the Zacks Industry Rank. On average, this group has gained an average of 7.3% so far this year, meaning that AMRN is slightly underperforming its industry in terms of year-to-date returns. Royalty Pharma is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Amarin and Royalty Pharma as they attempt to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Amarin (AMRN - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Amarin is a member of the Medical sector. This group includes 918 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Amarin is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for AMRN's full-year earnings has moved 26.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AMRN has moved about 2.1% on a year-to-date basis. In comparison, Medical companies have returned an average of 1.6%. This means that Amarin is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Royalty Pharma (RPRX - Free Report) . The stock is up 56.8% year-to-date.
For Royalty Pharma, the consensus EPS estimate for the current year has increased 5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Amarin belongs to the Medical - Biomedical and Genetics industry, a group that includes 439 individual companies and currently sits at #162 in the Zacks Industry Rank. On average, this group has gained an average of 7.3% so far this year, meaning that AMRN is slightly underperforming its industry in terms of year-to-date returns. Royalty Pharma is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Amarin and Royalty Pharma as they attempt to continue their solid performance.